OncoMatch/Clinical Trials/NCT07155226
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
Is NCT07155226 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including AZD3632 and Posaconazole for acute lymphoblastic leukaemia.
Treatment: AZD3632 · Posaconazole — The purpose of this study is to understand the safety, tolerability, efficacy, pharmacokinetic (PK), pharmacodynamic (PD), and preliminary efficacy of orally administered AZD3632 in participants with advanced haematologic malignancies with KMT2Ar, NPM1m, or other genotypes associated with homeobox (HOX) overexpression.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Myelodysplastic Syndrome
Biomarker criteria
Required: KMT2A (MLL) rearrangement
Required: NPM1 mutation
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: intensive chemotherapy — relapsed/refractory
Relapsed and primary refractory acute leukaemia after standard of care therapy including but not limited to 2 cycles of intensive chemotherapy, hypomethylating agent (HMA) monotherapy, or HMA combinations such as HMA/venetoclax
Must have received: hypomethylating agent — relapsed/refractory
Relapsed and primary refractory acute leukaemia after standard of care therapy including but not limited to 2 cycles of intensive chemotherapy, hypomethylating agent (HMA) monotherapy, or HMA combinations such as HMA/venetoclax
Must have received: hypomethylating agent — relapsed/refractory
Relapsed and primary refractory MDS is defined by ≥ 5% blasts in the bone marrow and/or persistence of peripheral blasts after treatment with at least 2 cycles of HMA
Cannot have received: menin inhibitor
Exception: backfill participants only
prior treatment other menin inhibitors (backfill participants only)
Cannot have received: investigational anticancer agent
Receipt of any investigational or non-investigational anticancer agents, including non-biologic agents, biologic agents
Cannot have received: non-investigational anticancer agent
Receipt of any non-investigational anticancer agents, including non-biologic agents and/or biologic agents
Cannot have received: radiation therapy
Exception: non-CNS radiation therapy within 2 weeks and CNS radiation within 8 weeks of the first scheduled dose
Receipt of non-CNS radiation therapy within 2 weeks and of CNS radiation within 8 weeks of the first scheduled dose
Cannot have received: radiation therapy
receipt of non-CNS or CNS radiation therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Research Site · Decatur, Illinois
- Research Site · New York, New York
- Research Site · Durham, North Carolina
- Research Site · Portland, Oregon
- Research Site · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07155226 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior menin inhibitor, investigational anticancer agent, non-investigational anticancer agent disqualifies patients from enrollment.
Does this trial require KMT2A?
Yes, KMT2A rearrangement is a required biomarker for enrollment.
Does this trial require NPM1?
Yes, NPM1 mutation is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify